AbbVie, Teva Accused Of Pay-For-Delay On Generic Niaspan

Law360, New York (April 4, 2013, 8:34 PM EDT) -- A union pension fund lodged an antitrust class action Thursday accusing AbbVie Inc. of paying off Teva Pharmaceuticals USA Inc. in a sham patent settlement to delay the release of a generic version of the cholesterol drug Niaspan.

The lawsuit, filed by the United Food & Commercial Workers Union and Midwest Health Benefits Fund, says collusion between AbbVie and generics maker Teva has kept a cheaper, nonbranded version of Niaspan off the market for eight years and driven up the price for end-purchasers.

So-called pay-for-delay cases...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.